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1.

Introduction
Candidiasis is a major opportunistic fungal infection in humans and its incidence has increased steadily over the last two decades due to the increasing number of susceptible individuals, such as transplant patients and HIV + individuals, 1 as well as the population ageing and the extensive use of aggressive antimicrobial and chemotherapeutic agents. [2] [3] [4] This situation is further aggravated due to the limited number of antifungal drugs commercially available, that does not allow an efficient control of the infection caused by this fungi. 5 For many years, fungal infections were treated with polyene compounds (Nystatin and Amphotericin B), despite their high toxicity. In the early 90s, the development of first generation triazoles (fluconazole and itraconazole) changed the epidemiology of candidiasis by offering new options for prevention and treatment. 6 However, the extensive use of these new antifungal agents has resulted in resistant strains, which now creates urgency for the development of new treatment strategies. 7, 8 Human candidiasis infections can range from a mild disease to a severe systemic infection that can be fatal. 9 Such variations occur, in large part, due to virulence factors that can determine the course of the infection. In candidiasis, these factors are responsible for the success of the colonization or infection in the host. Candida albicans, in particular, has developed an effective set of virulence attributes and specific strategies that can determine the course of infection. 10, 11 Although there are many virulence factors that have been attributed to C. albicans, hydrophobicity; adherence to the host tissues; morphological conversion to the filamentous form (dimorphism); recognition of surface molecules and enzymes production are considered the most important issues to date. [12] [13] [14] Therefore, considering the role of extracellular enzymes in the pathogenesis of candidiasis, the therapeutic use of protease inhibitors could act to reduce the virulence of C. albicans.
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The secreted leucocyte protease inhibitor (SLPI) is a cationic, non glycosylated protein, consisting of 107 amino acids with a low molecular weight (11.7 kDa), [16] [17] [18] [19] able to inhibit the activity of a large number of serine proteases. 17, 20, 21 SLPI can be found in several mucosal secretions, such as saliva, milk and semen, in different concentrations, ranging from 2.0 mM in saliva [22] [23] [24] [25] to 80 mM in seminal fluid. 26 The therapeutic potential of SLPI was demonstrated ''in vitro'' when applied on induced epidermal lesions, which resulted in the reduction of the lesion size, the tissue repair time and inflammation. 27, 28 In addition, SLPI antimicrobial features have already been reported. [29] [30] [31] [32] Therefore, the enzymatic inhibitory features of this protein associated to its antifungal activity suggest its potential for the development of new therapeutic strategies against candidiasis. Considering this, this study aimed to evaluate the antifungal potential of SLPI on C. albicans biological processes, which may contributes to the development of new strategies for therapeutics and prophylaxis of candidiasis. This study shows for the first time the ability of SLPI to modulate different virulence factors, such as: the proteolytic activity, hydrophobicity, adhesion to epithelium and mannoprotein expression on C. albicans. These factors were particularly selected due to its essential role in the very early stages of the infections, providing the installation of the disease. In addition, the ultrastructural changes that this protein causes on the yeast were evaluated by TEM.
2.
Materials and methods
Strains and culture conditions
Despite the emerging shift in the aetiology of candidiasis, C. albicans remains the most prevalent species in mucosal infections, [33] [34] [35] [36] skin infections 37 and in nosocomial candidemia. 38 Thus, two strains of C. albicans were chosen to be evaluated in this work. One clinical strain resistant to fluconazole, which was isolated from the oral mucosal of an HIV(+) patient, namely PRI, 39, 40 that was used in all experiments, and the ATCC 24433 reference strain, which was used in the MIC and in the minimal fungicidal concentration (MFC) assays. Before any experimental procedures, both strains were subcultured into Brain Heart Infusion (BHI) broth and incubated at 37 8C for 48 h for the yeasts to reach the exponential growing phase.
Recombinant protein
Recombinant SLPI protein and anti-hSLPI antibody were purchased from R&D System 1 (Minneapolis, USA) and reconstituted in phosphate-buffered saline PBS 10 mM, pH 7.2 at 25 8C.
MIC and MFC
SLPI MIC was determined according to the M27-A2 methodology for microdilution. Serial protein dilutions were prepared in the range from 80 to 0.62 mM, and fluconazole and nystatin were used as control. Microtitre plates were evaluated spectrophotometrically (600 nm), and the results were analyzed through the linear equation obtained by dispersion analysis in Microsoft Excel 1 . The minimum concentration able to inhibit yeast growth completely and 50% were defined as MIC and IC 50 , respectively. MFC was calculated by subculturing 10 mL of each well onto Sabouraud dextrose agar (SDA) medium in Petri dishes, and incubated at 37 8C for 24 h. The lowest protein concentration able to decrease yeast viability by 99.9% was considered to be MFC.
Proteolytic activity
The inhibitory function of SLPI towards the proteolytic activity of secreted serine proteinases from the C. albicans clinical strain was evaluated by the cleavage of the fluorogenic substrate Z-Phe-Arg-4-methoxy-b-naphthylamide (Sigma Aldrich 1 , St. Louis, USA). After a 48 h incubation in BHI medium, yeast cells were harvested by centrifugation for 8 min at 4 8C, the supernatant was filtered in a Millipore 1 (Billerica, MA, USA) membrane 0.22 mm and concentrated by ultrafiltration with an exclusion membrane of 10 kDa, for 7 h at 4 8C resulting in a 30Â concentrated solution. 8 The ) were incubated with 9.0 and 80 mM of SLPI for 6 h at 37 8C, washed in PBS 10 mM, pH 7.2 and fixed in 2.5% glutaraldehyde in sodium cacodylate buffer 0.1 M, pH 7.2 for 1 h. Fixed samples were washed and post-fixed in 1% osmium tetroxide in sodium cacodylate buffer 0.1 M, pH 7.2 containing 0.8% potassium ferrocyanide and 5 mM of CaCl 2 . Dehydration was carried out by increasing concentrations of acetone, and samples were embedded in epoxy resin to make the blocks which were polymerized at 60 8C for 72 h. Blocks were cut on an ultramicrotome and sections were placed on copper grids and contrasted in saturated uranyl acetate and lead citrate solution. Images were finally analyzed in a transmission electron microscope EM 900 1 (Zeiss, Oberkochen, Germany).
Statistical analyses
Flow cytometry final results were considered to be the representation of four independent experiments. All others experiments were performed at least in triplicate and results were expressed as mean AE standard deviation. Data were analyzed by the Student's t-test paired, and p values lower than 0.05 were considered significant.
Results
MIC and MFC
The MIC data of the clinical isolate and ATCC strain of C. albicans are summarized in Table 1 . The results show that SLPI was able to inhibit yeast growth in both strains in similar concentrations. Equivalence between molarity and weight/ volume concentrations was registered as well, and MIC and IC 50 were equivalent to 18 and 18.9 and 9.9 and 9.4 mM for the clinical isolate and ATCC 24433 strains, respectively. MFC for both strains were calculated as 20 mM, suggesting primarily a fungicidal activity.
Proteolytic activity
The proteolytic activity profile of secreted serine proteases released by the clinical isolate in the presence of different SLPI concentrations are summarized in Fig. 1 . The figure shows that the minimal physiologic concentration (2.0 mM) and MIC (18 mM) of SLPI were able to inhibit the proteolytic activity of serine protease secreted by C. albicans in 37.1% and 48.4%, respectively.
Hydrophobicity
Cell surface hydrophobicity was determined by the aqueoushydrocarbon biphasic partitioning assay and revealed that when the yeasts were incubated with the highest physiologic concentration (80 mM) of SLPI for 6 h at 37 8C, CSH reached 27.2%, whereas CSH was 16.1% in the incubation cells without SLPI, indicating an increase of 11.1% in the yeast CHS after SLPI treatment.
Surface receptors for SLPI
The histogram presented in Fig. 2 demonstrates that SLPI was able to recognize specific molecules on the surface of C. albicans. Fluorescence peaks moved to the right when yeast cells were treated with the lowest physiological concentration of SLPI 2 mM ( Fig. 2A ) and 9 mM of SLPI (Fig. 2B) . However this latter incubation shows a greater peak displacement, compared to the first one, pointing to a higher level of recognition. For confirmation, arbitrary fluorescent units (AFU) were measured, and they showed an increase in fluorescence emission of 21.1% and 70% when the yeasts were incubated with 2 and 9 mM of SLPI, respectively.
Cell wall mannoprotein expression
Flow cytometry analysis using concanavalin-A (con-A) as a probe for mannoproteins revealed that treatment with the IC 50 of SLPI (9.0 mM) did not alter the expression of receptors for the lectin on the surface of C. albicans (Fig. 3) . However, when cells were incubated with the highest physiologic concentration (80 mM) of SLPI, the flow cytometry analysis revealed a decrease in the expression of mannoproteins on the cell wall of the yeast. Considering only AFUs, there was a decrease of 20.8% in the fluorescence emitted by yeast cells treated with 80 mM of SLPI, while no shrinkage was observed in the 9.0 mM incubation.
Adhesion of C. albicans to epithelial cells
The influence of 18 mM of SLPI on the interaction between the clinical strain and MA 104 is demonstrated in Fig. 4 . SLPI was able to reduce the association index by 60.1%, as shown in Fig. 4(a) . Representative images of the interaction process are shown in Fig. 4(b) , where a clear distinction between the interaction patterns can be seen, strengthening the results of quantitative analysis.
Ultrastructure
Transmission electron microscopy revealed ultrastructural changes in cells treated with 9.0 (data not shown) and 80 mM of SLPI (Fig. 5) . Treatment with 80 mM SLPI caused cell deflation and structural changes such as the presence of disorganized membrane structures within the cytoplasmatic compartment.
Discussion
Growth inhibition can contribute substantially to control fungal infections, since the ability to limit the proliferation of rapidly growing fungi can decrease the onset of the disease in susceptible patients. 43 Fluconazole displays linear pharmacokinetics in dosages that can reach 50-800 mg/day, it has a high bioavailability, and low binding to circulating proteins, which provides an easy and quick access to patient's tissues. 3 Cutoff points that determine the resistance or susceptibility of C. albicans to fluconazole are well established and MIC values 
above 64 mg/mL and below 8 mg/mL define a strain as resistant or susceptible to this drug, respectively. 44 In this study, the evaluation of MIC showed distinct fluconazole values for the two strains of C. albicans, as expected. However, SLPI values were similar for both strains suggesting that the resistance mechanisms to fluconazole from the PRI strain were unable to affect SLPI activity. In fact, an MFS efflux pump was recently identified in the PRI strain as the main cause of its fluconazole resistance. 40 Therefore, similar MIC values for both susceptible and PRI strain makes us believe that this efflux mechanism may be ineffective against SLPI activity. Anyway, resistance to antifungal drugs has particular importance considering the limited number of commercially available drugs. 2 Thus, any new therapy able to circumvent this situation must be considered relevant. SLPI MIC values for both strains were higher than 17 mM, which remains within the range of physiological secretion. 26 Therefore, considering its constitutive features, it is likely that an exogenous administration of SLPI could fulfil its antifungal biological role without any adverse effects on the patient. 45 The administration of 17 mM of recombinant SLPI, by aspiration, on the bronchopulmonary epithelium of patients with cystic fibrosis reduced proteolytic activity and the expression of interleukin 8 (IL-8) providing a significant improvement in the inflammation. 46 The inhibitory values obtained in this study, although high, seem promising and reinforce the idea of using SLPI as a possible therapeutic alternative.
Regarding growth and viability; the results showed that MIC and MFC values were similar, pointing primarily to a fungicidal activity. Clinically, the selection criteria for antimicrobial drugs are universal, and postulate that whenever there is an option, the chosen drug must be microbicidal in the first place, 47 reinforcing the potential of SLPI as a therapeutic option in the future. The secreted protease activities of C. albicans have been associated with the increase in the virulence of this organism; therefore, the therapeutic use of protease inhibitors has been suggested as a potential alternative for the control and management of candidiasis. 11 The superfamily of subtilisinlike serine are reportedly responsible for activating protein precursors in Saccharomyces cerevisiae and C. albicans. 48 In these two genuses, a similar proenzyme prototype is Kex2p, which is a cytoplasmic serine protease involved in the expression of some pivotal virulence factors in C. albicans, including morphological differentiation and the clearance of extracellular proteases, which are factors considered essential to a successful infection. 12, 49, 50 In fact, this study demonstrated that the physiologic concentrations of SLPI were able to inhibit significantly the proteolytic activity of serine proteases secreted by C. albicans. Adhesive interactions are considered the initial step that leads to the establishment of infections caused by any microorganism, including Candida spp. 51, 52 The presence of SLPI during the interaction process between epithelial cells and C. albicans reduced it by more than 60%. Epithelial invasion by C. albicans is crucial to the pathogenesis of candidiasis and normally follows two different mechanisms: an active penetration, where C. albicans hyphae or germ tube elongates and pushes itself physically into the host cell, 53 and penetration by endocytosis, where adhesins bind to epithelial cell receptors and activate proper endocytosis machinery. 54 In fact, the role of serine proteinases in the adhesion process is considered crucial, as its inhibition by classical inhibitors, such as phenylmethylsulphonyl fluoride (PMSF) is able to downregulate association indexes to similar levels. 12 Histopathologically, the interaction process between fungal and epithelium can be considered a dynamic process that relies on proper features from the host, such as ageing or immunosuppression, and from the yeast such as hydrophobicity, positive net charge, presence of pathogen-associated molecular patterns (PAMP), and exposing of mannoproteins, among others. 55 CSH has been considered a non biological factor strongly related to the adhesion of fungal cells to host tissues, [56] [57] [58] and to the yeast resistance to phagocytosis by polymorphonuclear cells. 59 This feature probably occurs due to the presence of hydrophobic proteins that can promote the binding to extracellular matrix components. But it is also possible that CSH could facilitate specific interactions between receptors and their ligants on the surface of the fungus. 60 In 2004, Hazen 59 described for the first time, a hydrophobic surface protein constitutive of C. albicans namely CSH1p, which is expressed independently of environmental conditions, culture or cell morphology. Recently and using a similar methodology, it was reported that sub-inhibitory concentrations of gluconate chlorhexidine were able to reduce C. albicans CSH in a dose dependent manner regardless of a patient's characteristics such as diabetic, asthmatic or smoker. 61 However, this study revealed an increase of 11.1% in CSH after treatment with 80 mM of SLPI. The results obtained by Ellepola and co-workers (2013) 61 could be explained by chlorhexidine pharmacodynamics characteristics, because this compound acts directly on the cell membrane as a cationic detergent, while SLPI may be evolved in other biological processes, such as proteinases inhibition. 19 The surface of C. albicans has a variety of PAMPs, such as chitin, glucan, mannoproteins and glycolipids. These structures act as ligants for receptors that specifically recognize these patterns, normally present on the surface of the host cells. This host-fungal interaction exhibits features of a dynamic system, in which the same cell can easily switch between different morphological forms presenting different PAMPs at different moments of time, thereby modulating the 
survival and virulence of commensal fungi such as C. albicans.
62-64 C. albicans has the ability to mask certain cell wall components and unmask others, qualitatively changing the PAMPs that are exposed to the host. For instance, dectin-1 recognizes b-glucans on fungal cell walls and triggers immune responses by the production of pro and anti-inflammatory cytokines. However, while the yeast form displays b-glucans on its surface, the hyphal form shields its layer of b-glucans underneath a coat of mannoproteins. 65 On the assumption that C. albicans expresses molecules capable of binding to SLPI, flow cytometry analysis was carried out. The results showed that the cells were strongly recognized by the anti-hSLPI, in a dosedependent manner, suggesting the existence of binding sites for this protein on the surface of C. albicans, which can contribute to the construction of alternative models to manage infections caused by this organism by blocking these sites. Cell wall glycoconjugates have an important role in the interaction between fungus and host cells. 66 To evaluated the effect of SLPI on the expression of cell surface mannoproteins of C. albicans, this study used FITC labelled Concanavalin A due to its ability to bind to mannose residues. The results showed that treatment with 9.0 mM of SLPI was not enough to change the availability of mannoproteins on the cell wall. However treatment with the maximal physiologic concentration (80 mM) reduced the binding of concanavalin A to the cell surface by 20%, pointing to a possible reduction in the expression of cell wall mannoproteins or a decreasing in mannose residues available for the connection to the lectin. In fact, con-A has been employed as a viable marker to evaluate the expression of mannans and mannoproteins on the surface of microorganisms. 67 These structures have a key role not only in maintaining the structural integrity of the cell, but also in the process of adhesion to host cells. 68, 69 Thus, the possible reduction in the expression of mannoproteins in C. albicans, as suggested by treatment with 80 mM of SLPI indicates an important potential on modulating one virulence factor that can impair yeast adhesion to the epithelium. As previously stated, fungal cell walls are complex, dynamic and highly adaptable organelle. C. albicans alters the phenotype of its wall by changing mannoproteins and polymer distribution in response to environmental conditions. Hence, some authors have already speculated that the variation in fungal cell wall phenotypes may have important implications for hostpathogen interactions. 70 The effect of SLPI on the ultrastructure of C. albicans was evaluated by TEM. Yeasts treated with 80 mM of SLPI revealed cytoplasmatic deflation, and the presence of disorganized plasmatic membrane like structures on the inner side of the plasma membrane within the cytoplasm compartment. This result suggests that the SLPI protein was able to overcome the cell wall and interact with the cytoplasmic membrane or at least interfere with the synthesis of its components. In fact, a previous study has already reported structural changes in the plasmatic membrane after the treatment of Cryptococcus neoformans with inhibitors of the synthesis of ergosterol 71 similar to this study.
In summary, the results obtained in this study point to the possible application of SLPI as a viable alternative in the treatment and management of infections caused by C. albicans, since this inhibitor was able to exert an important influence on the viability and on relevant virulence mechanisms of C. albicans. Considering this, the exogenous administration of this protein could perhaps become a viable therapeutic alternative in the future, even for C. albicans resistant strains, overcoming toxicity issues, considering its constitutive and physiological features.
